RedHill Biopharma (RDHL) Change in Accured Expenses (2012 - 2025)

RedHill Biopharma (RDHL) has 12 years of Change in Accured Expenses data on file, last reported at $456000.0 in Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at $456000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $456000.0 (changed N/A YoY), and the FY2025 annual result was $456000.0, down 85.01% from the prior year.
• Change in Accured Expenses improved to $456000.0 in Q4 2025 per RDHL's latest filing, from -$3.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.3 million in Q1 2022 and troughed at -$3.2 million in Q4 2022.
• A 3-year average of -$437333.3 and a median of $309000.0 in 2021 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 138.64% in 2022 and fell as far as 1151.78% in 2022.
• A 3-year view of Change in Accured Expenses shows it stood at $309000.0 in 2021, then plunged by 1151.78% to -$3.2 million in 2022, then soared by 114.03% to $456000.0 in 2025.
• Business Quant data shows RDHL's Change in Accured Expenses at $456000.0 in Q4 2025, -$3.2 million in Q4 2022, and $987000.0 in Q3 2022.